Please use this identifier to cite or link to this item: https://doi.org/10.1038/srep24786
Title: KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer
Authors: Liu, Y.-Z
Yang, H
Cao, J
Jiang, Y.-Y 
Hao, J.-J
Xu, X
Cai, Y
Wang, M.-R
Keywords: antineoplastic agent
KRAS protein, human
messenger RNA
protein p21
tumor marker
adult
aged
Carcinoma, Non-Small-Cell Lung
female
gene expression regulation
genetics
human
Kaplan Meier method
lung tumor
male
metabolism
middle aged
mortality
prognosis
proportional hazards model
signal transduction
treatment outcome
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Female
Gene Expression Regulation, Neoplastic
Humans
Kaplan-Meier Estimate
Lung Neoplasms
Male
Middle Aged
Prognosis
Proportional Hazards Models
Proto-Oncogene Proteins p21(ras)
RNA, Messenger
Signal Transduction
Treatment Outcome
Issue Date: 2016
Citation: Liu, Y.-Z, Yang, H, Cao, J, Jiang, Y.-Y, Hao, J.-J, Xu, X, Cai, Y, Wang, M.-R (2016). KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer. Scientific Reports 6 : 24786. ScholarBank@NUS Repository. https://doi.org/10.1038/srep24786
Rights: Attribution 4.0 International
Abstract: Nowadays, no robust biomarkers have been applied to clinical practice to provide prognostic evaluation of non-small cell lung cancer (NSCLC). This study aims to identify new potential prognostic biomarkers for NSCLC. In the present work, KIAA1522 is screened out from two independent GEO datasets as aberrantly up-regulated gene in NSCLC tissues. We evaluate KIAA1522 expression immunohistochemically in 583 NSCLC tissue samples and paired non-tumor tissues. KIAA1522 displays stronger staining in NSCLC cases than in adjacent normal lung tissues. Importantly, patients with KIAA1522 overexpression had a significantly shorter overall survival compared to those with low expression (P < 0.00001). Multivariate Cox regression analyses show that KIAA1522 is an independent prognostic indicator, even for early-stage NSCLCs (P = 0.00025, HR = 2.317, 95%CI: 1.477-3.635). We also found that high expression of KIAA1522 is a significant risk factor for decreased overall survival of the patients who received platinum-based chemotherapy. Gene set enrichment analysis (GSEA) and functional studies reveal that KIAA1522 is associated with oncogenic KRAS pathways. Taken together, high expression of KIAA1522 can be used as an independent biomarker for predication of poor survival and platinum-resistance of NSCLC patients, and aberrant KIAA1522 might be a new target for the therapy of the disease.
Source Title: Scientific Reports
URI: https://scholarbank.nus.edu.sg/handle/10635/178917
ISSN: 20452322
DOI: 10.1038/srep24786
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_srep24786.pdf6.2 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

10
checked on Mar 3, 2021

Page view(s)

29
checked on Mar 4, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons